Eisai Targeted Again Over Aciphex Patent

Law360, New York (March 23, 2007, 12:00 AM EDT) -- For the second time in less than six months, Eisai Co. Ltd. has been slapped with an antitrust lawsuit that claims the Japanese drug maker attempted to prevent a generic version of its lucrative ulcer drug Aciphex from hitting the market by duping patent examiners.

The proposed class action, filed on Wednesday in the U.S. District Court for the Southern District of New York, was brought by Stephen L. LaFrance Holdings Inc., a holding company with interests in retail stores and wholesale drug distribution, and its...
To view the full article, register now.